Human Mature PCSK9 (153-692) Protein
- Known as:
- Human Mature PCSK9 (153-692) Protein
- Catalog number:
- PC9-H5226
- Product Quantity:
- 200ug
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human Mature PCSK9 (153-692) Protein
Related genes to: Human Mature PCSK9 (153-692) Protein
- Gene:
- PCSK9 NIH gene
- Name:
- proprotein convertase subtilisin/kexin type 9
- Previous symbol:
- HCHOLA3
- Synonyms:
- NARC-1, FH3
- Chromosome:
- 1p32.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-13
- Date modifiied:
- 2019-04-23
Related products to: Human Mature PCSK9 (153-692) Protein
Related articles to: Human Mature PCSK9 (153-692) Protein
- Radiation-induced brain injury (RIBI) is a serious complication of cranial radiotherapy, yet its molecular mechanisms remain unclear. This study aimed to identify novel therapeutic targets for RIBI through integrated dual-omics analysis. - Source: PubMed
Publication date: 2026/08/29
Li XuejiaoShu KunHe XiaoZhou MinDing Zhongxiang - Long noncoding RNAs (lncRNAs) are key regulators of vascular endothelial function. The lncRNA differentiation antagonizing non-protein coding RNA (DANCR) is implicated in cell proliferation and inflammatory responses; however, its specific role in atherosclerosis remains undefined. - Source: PubMed
Publication date: 2026/08/29
Wang ShutingZhang QiyueLi RongxiaWang YixiaoKamili AdalaitiHan YuqingHou ZhihuiChen YuYang ShujunZhang Weili - - Source: PubMed
Publication date: 2026/08/29
Bonanni LucaSchiele FrançoisAboyans VictorKoskinas Konstatinos - Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition is recommended as second- or third-line lipid-lowering therapy after myocardial infarction (MI), resulting in prolonged periods of inadequate low-density lipoprotein cholesterol (LDL-C) control. Whether in-catheterization laboratory decision of PCSK9 inhibition, started before mechanical reperfusion, could improve LDL-C control and clinical outcomes at 1 year is unknown. - Source: PubMed
Publication date: 2026/08/29
Montalescot GillesFerrari EmileSouteyrand GéraudBouleti ClaireRange GrégoireBatias-Moreau LaureChioccioli MarcoPicchi AndreaDillinger Jean-GuillaumeEsposito GiovanniPatti GiuseppeVincent FlavienBraik NassimEderhy StéphaneCoste PierreHannachi SindaRedjimi NassimZeitouni MichelDuband BenjaminFourrier EtienneGuedeney PaulProcopi NikiSabouret PierreDiallo AbdourahmaneBrochard KarineChamam AmelVignolles NicolasKerneis MathieuSilvain JohanneJukema J WouterMach FrançoisCequier-Fillat AngelThiele HolgerBartus StanislawBolognese LeonardoVicaut Eric - Beneficial effects of the gut commensal Agathobacter rectalis (Ar) are reported in diseases, yet its role in colorectal cancer (CRC) remains unclear. Here, metagenomic analysis revealed consistent fecal Ar depletion across CRC cohorts. In mice, Ar inhibited colon tumorigenesis, reducing tumor number and volume versus E. coli and PBS controls. LC-MS/MS metabolomics showed decreased fecal cholesterol and altered lipid/cholesterol pathways after Ar treatment. , Ar-conditioned medium suppressed CRC cell growth, clonogenicity, migration, and cell cycle progression. LC-MS/MS identified (-)-epigallocatechin (EGC) as an Ar-derived metabolite absent in control bacteria. EGC recapitulated Ar-mediated anti-CRC effects and , with metabolic changes linked to lipid/cholesterol pathways. Transcriptomics showed that EGC suppressed SREBP signaling, cholesterol metabolism, and MAPK pathways. Mechanistically, EGC reduced nuclear SREBF2 and its transcriptional activity, downregulated cholesterol synthesis/metabolism genes, including FDPS and PCSK9, and suppressed MAPK signaling. Molecular docking suggested that EGC may bind pSREBF2 or SCAP. Cellular thermal shift assay revealed that EGC interacts with and stabilizes pSREBF2, but not SCAP. Co-immunoprecipitation demonstrated that EGC reduces pSREBF2-SCAP interaction, thereby inhibiting SCAP-mediated SREBF2 cleavage activation. Together, these findings define an Ar-EGC microbe-metabolite axis and support Ar/EGC-based interventions targeting cholesterol metabolism in CRC. - Source: PubMed
Publication date: 2026/08/28
Lu JiaweiSun YutingZeng YaoLau Effie Yin TungLan ZhienYe SilinZhang RuiHu RuoyuCui ChunhuiLiang Jessie Qiaoyi